98%
921
2 minutes
20
People tend to generalize the actions of known group members to new ones when they are both members of the same group. This study was conducted to investigate how the prevalence of specific actions among multiple individuals determines action generalization within social groups. We propose that people rely on the belief that group members work toward a shared goal (i.e., shared-goal belief) to guide action generalization. Consequently, the extent of action generalization may not consistently increase with the sampled prevalence of group members performing the same goal-directed action, resulting in a deviation from graded action generalization (i.e., nongraded action generalization). Experiment 1 revealed that the more participants believed that group members pursued a shared goal, the greater the likelihood that nongraded action generalization would occur. In Experiment 2, experimental manipulation weakened the strength of the shared-goal belief and led to a graded pattern of action generalization with accumulated evidence of action prevalence. These findings suggest that a shared-goal belief within groups significantly shapes action generalization beyond the mere influence of sampled action prevalence. Social groups not only provide a framework for selecting evidence for action generalization but also shape prior beliefs that influence our expectations of others' actions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380659 | PMC |
http://dx.doi.org/10.1186/s41235-025-00666-x | DOI Listing |
JMIR Res Protoc
September 2025
Department of Food Science and Technology, Kaunas University of Technology, Kaunas, Lithuania.
Background: Fermented foods vary significantly by food substrate and regional consumption patterns. Although they are consumed worldwide, their intake and potential health benefits remain understudied. Europe, in particular, lacks specific consumption recommendations for most fermented foods.
View Article and Find Full Text PDFBioDrugs
September 2025
Department of Nephrology, Instituto de Investigación Hospital "12 de Octubre" (imas12), Avda. De Córdoba s/n, 28041, Madrid, Spain.
Anti-CD20 monoclonal antibodies are gaining clinical relevance in the nephrology community due to their demonstrated efficacy and favorable safety profiles across short-, medium-, and long-term use. Initially developed for hematologic malignancies and multiple sclerosis, B-cell depletion therapies are now being investigated across a broader spectrum of autoimmune diseases, including glomerulopathies, both with and without associated podocytopathy. Recent advances have led to the development of novel anti-CD20 agents that are being used not only as potential alternatives to corticosteroids but also as adjunctive therapies in complex clinical settings.
View Article and Find Full Text PDFCardiol Rev
September 2025
From the Department of General Medicine, J.S.S. Medical College, JSS Academy of Higher Education and Research, Mysuru, India.
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and is increasing in prevalence due to aging populations and comorbidities such as hypertension and diabetes. While echocardiography remains the diagnostic cornerstone, many patients with preserved ejection fraction present with nonspecific symptoms and ambiguous diastolic indices, leading to diagnostic uncertainty and therapeutic delay. Arterial stiffness-quantified by pulse wave velocity, augmentation index, and cardio-ankle vascular index)-is emerging as a key contributor to HFpEF pathophysiology.
View Article and Find Full Text PDFNeuropsychiatr Dis Treat
August 2025
Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA.
Brexpiprazole is a second-generation antipsychotic with multiple indications, including the treatment of schizophrenia. As a partial dopamine agonist, brexpiprazole differs from most other antipsychotics, yet uncertainties about its full mechanism of action have led to some ambiguity among prescribers. To address this gap, an international panel of psychiatric experts was organized and convened with funding from Otsuka Pharmaceutical Europe Ltd and H.
View Article and Find Full Text PDF